IDXX — IDEXX Laboratories, Inc. stock price, charts and financials

QT35IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
599.93
+13.26+2.26%
IDXXQT35IDEXX Laboratories, Inc.·NASDAQ
599.93+2.26%
News
Up 2.3% — IDEXX Laboratories: Worth The Premium (seekingalpha.com).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500, NDXP/E41.20EPS (ttm)14.24Insider Own0.91%Shs Outstand78.88MPerf Week4.94%
Market Cap46.28BForward P/E35.05EPS next Y16.74Insider Trans-6.42%Shs Float78.58MPerf Month5.03%
Enterprise Value47.05BPEG2.33EPS next Q-Inst Own66.43%Short Float2.67%Perf Quarter2.53%
Income1.12BP/S10.16EPS this Y8.62%Inst Trans-Short Ratio3.21Perf Half Y-8.84%
Sales4.55BP/B29.14EPS next Y13.65%ROA33.11%Short Interest2.10MPerf YTD-13.28%
Book/sh-P/C34.36EPS next 5Y14.84%ROE71.96%52W High787.41 -23.81%Perf Year-6.01%
Cash/sh-P/FCF37.01EPS past 3/5Y17.66% 14.28%ROIC41.33%52W Low530.25 13.14%Perf 3Y13.00%
Dividend Est.-EV/EBITDA29.84Sales past 3/5Y8.53% 9.72%Gross Margin62.45%Volatility4.19% 3.17%Perf 5Y-13.54%
Dividend TTM-EV/Sales10.33EPS Y/Y TTM27.09%Oper. Margin32.03%ATR (14)20.13Perf 10Y529.41%
Dividend Ex-Date-Quick Ratio0.87Sales Y/Y TTM14.06%Profit Margin25.03%RSI (14)59.76Recom2.48
Dividend Gr. 3/5Y-Current Ratio1.17EPS Q/Q17.23%SMA204.01%Beta1.53Target Price685.00
Payout0.00%Debt/Eq0.60Sales Q/Q14.33%SMA504.77%Rel Volume0.87Prev Close586.67
Employees11,000LT Debt/Eq0.36EarningsNov 02SMA200-5.24%Avg Volume667.83KPrice599.93
IPO DateJun 21, 1991Option/ShortYes / YesEPS/Sales Surpr.1.76% 2.00%Net Debt/EBITDA0.49Volume583,351Change2.26%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-27-26ReiteratedUBSNeutral$640$620
Apr-28-26ReiteratedUBSNeutral$730$640
Feb-09-26ReiteratedPiper SandlerNeutral$750
Feb-05-26ReiteratedBarclaysOverweight$850$800
Feb-03-26ReiteratedUBSNeutral$750$730
Feb-03-26ReiteratedBTIGBuy$830$800
Dec-08-25InitiatedBarclaysOverweight$590$850
Nov-04-25ReiteratedJefferies$830
Nov-04-25ReiteratedMorgan StanleyOverweight$722$805
Nov-04-25ReiteratedBTIGBuy$785$830
Latest News
Aug-08-26
Aug-08-2608:00AM
Aug-06-26
Aug-04-26
Jul-31-26
Jul-28-26
Company

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Ownership
Total institutional ownership66.43%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,5544,3043,898
Cost of Goods Sold Incl. D&A1,7091,6441,519
Gross Profit2,8432,6602,379
Selling, General and Administrative Excl. Other1,1231,0481,031
Research and Development261251220
Other Operating Expense210
Operating Income1,4601,3601,128
Interest Expense403831
Unusual Expense
Non-Operating Income (Expense)6213
Net Income Before Taxes1,4241,3241,110
Income Taxes285265222
Consolidated Net Income1,1391,059888
Net Income From Continuing Operations1,1391,059888
Net Income1,1391,059888
EPS (Recurring)14.2413.1710.77
EPS (Basic, Before Extraordinaries)14.2413.1710.77
EPS (Diluted)14.1213.0810.67
EBITDA1,5761,4691,276
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio42.4951.7238.75
Price To Sales Ratio10.5412.578.70
Gross Margin62.4361.8061.03
Operating Margin32.0631.6028.94
Net Margin25.0124.6122.78
Shares Outstanding808082
Market Capitalization47,99454,12233,902
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$804.68$722.35$640.02$557.69$475.36 Close Price0.00M8.57M17.15M25.72M34.29MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FENNELL GEORGEExecutive Vice PresidentJun 01 '26Option Exercise0.00639010,717Jun 02
Vandebroek Sophie V.DirectorMay 07 '26Option Exercise0.002570905May 11
SZOSTAK M ANNEDirectorMay 07 '26Option Exercise0.002570519May 11
Peacock KarenDirectorMay 07 '26Option Exercise0.001010102May 11
Kingsley Lawrence DDirectorMay 07 '26Option Exercise0.0033909,568May 11
JUNIUS DANIEL MDirectorMay 07 '26Option Exercise0.0025703,561May 11
HOOLEY JOSEPH LDirectorMay 07 '26Option Exercise0.001580276May 11
Underberg Sharon E.EVP, GC & Corporate SecretaryMar 03 '26Option Exercise505.5319799,5897,138Mar 05
Hunt NimrataExecutive Vice PresidentMar 03 '26Sale634.571,7581,115,57718,141Mar 05
MAZELSKY JONATHAN JAYPresident and CEOFeb 27 '26Option Exercise505.5319799,58983,803Mar 02
MAZELSKY JONATHAN JAYPresident and CEOFeb 26 '26Sale657.5523,32615,338,08283,606Mar 02
MAZELSKY JONATHAN JAYPresident and CEOFeb 26 '26Option Exercise141.6023,3263,302,962106,932Mar 02
Hunt NimrataExecutive Vice PresidentFeb 26 '26Sale661.542,6931,781,53119,899Feb 27
Erickson Michael GExecutive Vice PresidentFeb 19 '26Option Exercise227.832,399546,55615,092Feb 19
Vandebroek Sophie V.DirectorFeb 17 '26Sale628.621,464920,293648Feb 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.